诚益生物
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Eccogene Enters Exclusive License Agreement With AstraZeneca to Develop and Commercialize Small Molecule GLP-1 Receptor Agonist ECC5004 for Cardiometabolic Diseases 2023-11-09 15:05
Eccogene Raises CNY 180 Million in Series B Equity Financing, Propelling its Pipeline of Treatments for Metabolic Diseases 2023-06-12 08:00
Eccogene Announces US IND Approval for GLP-1 Receptor Agonist ECC5004 2022-11-03 13:11
Eccogene Announces US IND Approval for THRβ agonist ECC4703 2022-08-01 15:00
Eccogene Announces Completed First-in-human of ECC0509 in Phase 1a Clinical Trial in Australia 2021-07-28 17:13
Eccogene announces the addition of Jacques Mizrahi, PhD to Scientific Advisory Board 2021-06-17 19:49
1